ArticleFrontiers in oncology2026
Risk prediction model for radiation pneumonitis in breast cancer radiotherapy based on dose-volume parameters combined with the neutrophil-to-lymphocyte ratio.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop and validate a risk prediction model for radiation pneumonitis (RP) and radiation-induced pulmonary fibrosis (RIPF) following breast cancer radiotherapy by integrating the V40 dose-volume parameter with the neutrophil-to-lymphocyte ratio (NLR), providing guidance for individualized treatment strategies. Methods: This retrospective cohort study analyzed clinical data from 164 patients with breast cancer who underwent postoperative radiotherapy between May 2018 and August 2020. Clinical-pathological characteristics, radiotherapy dosimetric parameters and NLR values were collected at three time points: pre-surgery, 1 week before radiotherapy and 1 month after radiotherapy. Radiation pneumonitis (0-6 months) and RIPF (≥6 months) were assessed according to the Common Terminology Criteria for Adverse Events (version 5.0). Receiver operating characteristic (ROC) curves were used to determine the optimal predictive indicators. Variable selection was performed using least absolute shrinkage and selection operator regression followed by multivariate logistic regression to construct the prediction model. Internal validation was conducted using 1,000 bootstrap resampling iterations. Results: Of the 164 patients, 107 (65.2%) developed varying degrees of RP (grade 1: n = 103, 62.8%; grade 2: n = 4, 2.4%), and 118 (72.0%) developed RIPF (all grade 1). The ROC analysis revealed that ipsilateral lung V40 had superior predictive performance for RIPF (area under the curve [AUC] = 0.728, 95% confidence interval [CI]: 0.651-0.805, cutoff value: 10.45%). The pre-radiotherapy NLR showed significant predictive value for RP (AUC = 0.685, 95% CI: 0.605-0.765, cutoff value: 2.82). Multivariate analysis identified independent risk factors for RP: V40 ≥ 10.45% (odds ratio [OR] = 3.24, 95% CI: 1.78-5.89, P < 0.001), pre-radiotherapy NLR ≥ 2.82 (OR = 2.56, 95% CI: 1.42-4.61, P = 0.002) and regional nodal irradiation (OR = 2.13, 95% CI: 1.18-3.84, P = 0.012). The combined prediction model achieved an AUC of 0.816 (95% CI: 0.748-0.884), significantly outperforming single indicators (ΔAUC = 0.088-0.131, P < 0.05). Bootstrap internal validation demonstrated robust model stability (C-index = 0.803). Conclusions: The integrated prediction model combining V40 and the NLR effectively identifies patients a high risk of RP following breast cancer radiotherapy, facilitating personalized treatment planning and early intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.